JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm.
The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its CDMO platform and creating a differentiated, end-to-end development and manufacturing offering spanning early development directly by Scinai and late-stage clinical and commercial supply by Recipharm. Under the collaboration agreement, development activities and tech transfer will be set up between the companies in a manner designed to facilitate an efficient and frictionless graduation of Scinai clients to Recipharm at the appropriate stage. As a result of the acquisition and the collaboration agreement, Scinai's expanded capabilities will now cover recombinant proteins, small molecules, peptides, antibodies and oligonucleotides through a combination of internal capabilities and collaboration with Recipharm.
Acquisition of Recipharm Israel Ltd.
Under the terms of the Share Purchase Agreement, Scinai has acquired Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, providing early chemistry development and small-scale manufacturing of active pharmaceutical ingredients (APIs) for biopharmaceutical customers' clinical programs. The acquisition was structured as a share purchase to preserve full operational continuity, including employees, quality systems, regulatory approvals, customer contracts, and ongoing operations. The transaction was structured such that Recipharm Israel was transferred with an appropriate working capital position at closing, consistent with maintaining operational continuity.
Following closing, the Yavne site will continue to operate as part of Scinai's CDMO platform, complementing Scinai's existing Jerusalem-based capabilities in early-stage development, analytics, and clinical manufacturing.
The financial terms of the Share Purchase Agreement remain confidential.
Strategic Commercial Collaboration with Recipharm
Concurrently with the acquisition, Scinai and Recipharm entered into a comprehensive Commercial Collaboration Agreement designed to support customer projects across the full development lifecycle.
The collaboration framework provides that:
-- Scinai will serve as a preferred partner for early-stage development and
clinical manufacturing projects within the Recipharm ecosystem.
-- Recipharm will serve as one of Scinai's preferred partners for late-stage
clinical and commercial manufacturing, subject to capacity and technical
suitability.
-- Scinai will have access to Recipharm's global manufacturing network,
under predefined commercial terms, providing the ability to support
client programs that extend beyond the capabilities of Scinai's internal
manufacturing footprint, including the newly acquired Yavne site.
-- The parties will mutually refer client projects and share economics as
programs transition from early-stage development at Scinai to late-stage
or commercial manufacturing at Recipharm.
As part of the collaboration, the parties have agreed to establish a Master Quality Agreement and a Tech Transfer Framework Agreement, creating a pre-defined contractual basis for quality alignment, regulatory compliance, and efficient transfer of client programs across development stages.
Strategic Rationale and Expected Benefits
The acquisition of Recipharm's manufacturing capabilities in Israel expands Scinai's CDMO footprint in Israel and adds complementary capabilities to its existing Jerusalem site. The Yavne facility broadens Scinai's technical scope and service offering, enabling access to additional customer segments and project types.
Key expected benefits include expanded support for small-molecule programs alongside peptides and liposomes, enhanced handling of complex and hazardous materials, and access to operating infrastructure and equipment that strengthen Scinai's industrial credibility, service breadth, and potential client base.
The Commercial Collaboration Agreement is intended to materially enhance Scinai's competitive positioning in two principal ways. First, it expands the breadth of Scinai's service offerings by enabling the subcontracting of selected capabilities from Recipharm under predefined commercial terms, while allowing Scinai to retain control over project management and optimize service delivery and execution speed by leveraging capacity across its internal operations and, where available, Recipharm's network. Second, it links Scinai's early-stage CDMO offering with Recipharm's global late-stage and commercial manufacturing footprint.
This structure allows Scinai's clients to begin engaging with Recipharm early in development as Scinai's preferred partner for late-stage clinical supply and to benefit from a seamless transition as programs advance. These transitions will be supported by a Master Quality Agreement and a Tech Transfer Framework Agreement to be executed between the parties following closing.
Strategically, this aspect of the collaboration addresses a common industry challenge faced by clients of smaller CDMOs: the risk of friction, delay, and cost overruns when programs transition to a global late-stage or commercial manufacturer. By pre-aligning quality systems, tech-transfer processes, and commercial incentives, the collaboration is designed to streamline these transitions and maintain continuity of service as client programs scale. This positioning differentiates Scinai among smaller CDMOs by offering clients an integrated, end-to-end development pathway from early stage through commercialization.
The collaboration also enables Scinai to participate economically in client programs that successfully progress to later-stage clinical supply or commercial manufacturing at Recipharm's facilities and includes structured referral economics, joint marketing and business development initiatives, and defined name-rights provisions.
Management Commentary
"This transaction fundamentally strengthens Scinai's CDMO platform," said Amir Reichman, Chief Executive Officer of Scinai. "By combining our early-stage development strengths with Recipharm Israel's manufacturing capabilities and Recipharm's global footprint, we are creating a differentiated offering that supports clients from early development through commercialization. Importantly, the collaboration allows Scinai to participate in the long-term success of client programs while maintaining capital discipline and operational focus."
"Ensuring continuity for the Yavne site, its employees and its customers was a key priority for us, and we are pleased to pair that with a strategic collaboration with Scinai," said Greg Behar, Chief Executive Officer of Recipharm. "The agreement creates a clear pathway for programs to progress efficiently into Recipharm's global development and commercial manufacturing network."
About Recipharm Israel Ltd.
Recipharm Israel Ltd. operates a cGMP development and manufacturing facility in Yavne, Israel, dedicated to early chemistry development and small-scale manufacturing of active pharmaceutical ingredients (APIs) for clinical programs. The site supports projects from first synthesis through Phase I and Phase II clinical supply and serves biopharmaceutical customers across multiple geographies.
The Yavne facility comprises approximately 900 square meters of built area and includes multiple production rooms, analytical laboratories, an R&D laboratory, and controlled cleanroom environments. The site provides integrated capabilities spanning medicinal chemistry, route scouting and optimization, scale-up development, analytical method development and validation, stability studies, and small-batch cGMP manufacturing for toxicology and clinical studies.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation $(CDMO)$ employing over 5,000 employees worldwide. Recipharm provides expertise in development and manufacturing across oral dosage, sterile fill & finish and advanced biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.
For more information on Recipharm, please visit www.recipharm.com and www.recipharm-ab.com
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units:
-- Scinai Bioservices, a boutique CDMO providing analytical method
development, process development, and clinical cGMP manufacturing
services for biotech clients worldwide.
-- Scinai R&D, focused on developing innovative inflammation and immunology
therapeutics based on NanoAbs (VHH antibody fragments) with unique
physicochemical properties suitable for advanced mono- and multi-specific
antibody formats.
Company website: www.scinai.com
Company Contacts
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2026 07:00 ET (12:00 GMT)